H2N2V1, Istex, Corpus, bibRecord, 001355

CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN

Identifieur interne : 001355 ( Istex/Corpus ); précédent : 001354; suivant : 001356

CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN

Auteurs : T. W. Hoskins ; Joanr. Davies ; A. Allchin ; Christinel. Miller ; T. M. Pollock

Source :

The Lancet [ 0140-6736 ] ; 1973.

RBID : ISTEX:1E3A706172CB5F0CC5025332A21D19D172754180

English descriptors

Teeft :
- American controls, American patients, Antibody, Antibody response, Antigenic shift, Cancer inst, Clinical influenza, Control group, Control groups, Essential aminoacids, Hong kong strain, Influenza, Influenza outbreak, Influenza vaccine, Influenza vaccines, Influenza virus, Kong strain, Levine, Maize, Maize diets, Maize variant, Medical officer, Normal maize, October, Outbreak, Prevaccination antibody, Public health laboratory, Recent antigenic shift, Significant reduction, Substantial protection, Vaccination, Vaccine, Virus strain.

Abstract

Abstract: A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.

Url:

https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/fulltext.pdf

DOI: 10.1016/S0140-6736(73)93062-6

Links to Exploration step

ISTEX:1E3A706172CB5F0CC5025332A21D19D172754180

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
<author><name sortKey="Hoskins, T W" sort="Hoskins, T W" uniqKey="Hoskins T" first="T. W." last="Hoskins">T. W. Hoskins</name>
<affiliation><mods:affiliation>Christ's Hospital, Horsham, Sussex, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Davies, Joanr" sort="Davies, Joanr" uniqKey="Davies J" first="Joanr." last="Davies">Joanr. Davies</name>
<affiliation><mods:affiliation>Public Health Laboratory, Guildford, Surrey, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allchin, A" sort="Allchin, A" uniqKey="Allchin A" first="A." last="Allchin">A. Allchin</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Miller, Christinel" sort="Miller, Christinel" uniqKey="Miller C" first="Christinel." last="Miller">Christinel. Miller</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pollock, T M" sort="Pollock, T M" uniqKey="Pollock T" first="T. M." last="Pollock">T. M. Pollock</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1E3A706172CB5F0CC5025332A21D19D172754180</idno>
<date when="1973" year="1973">1973</date>
<idno type="doi">10.1016/S0140-6736(73)93062-6</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001355</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001355</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
<author><name sortKey="Hoskins, T W" sort="Hoskins, T W" uniqKey="Hoskins T" first="T. W." last="Hoskins">T. W. Hoskins</name>
<affiliation><mods:affiliation>Christ's Hospital, Horsham, Sussex, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Davies, Joanr" sort="Davies, Joanr" uniqKey="Davies J" first="Joanr." last="Davies">Joanr. Davies</name>
<affiliation><mods:affiliation>Public Health Laboratory, Guildford, Surrey, United Kingdom</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Allchin, A" sort="Allchin, A" uniqKey="Allchin A" first="A." last="Allchin">A. Allchin</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Miller, Christinel" sort="Miller, Christinel" uniqKey="Miller C" first="Christinel." last="Miller">Christinel. Miller</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Pollock, T M" sort="Pollock, T M" uniqKey="Pollock T" first="T. M." last="Pollock">T. M. Pollock</name>
<affiliation><mods:affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">The Lancet</title>
<title level="j" type="abbrev">LANCET</title>
<idno type="ISSN">0140-6736</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1973">1973</date>
<biblScope unit="volume">302</biblScope>
<biblScope unit="issue">7821</biblScope>
<biblScope unit="page" from="116">116</biblScope>
<biblScope unit="page" to="120">120</biblScope>
</imprint>
<idno type="ISSN">0140-6736</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>American controls</term>
<term>American patients</term>
<term>Antibody</term>
<term>Antibody response</term>
<term>Antigenic shift</term>
<term>Cancer inst</term>
<term>Clinical influenza</term>
<term>Control group</term>
<term>Control groups</term>
<term>Essential aminoacids</term>
<term>Hong kong strain</term>
<term>Influenza</term>
<term>Influenza outbreak</term>
<term>Influenza vaccine</term>
<term>Influenza vaccines</term>
<term>Influenza virus</term>
<term>Kong strain</term>
<term>Levine</term>
<term>Maize</term>
<term>Maize diets</term>
<term>Maize variant</term>
<term>Medical officer</term>
<term>Normal maize</term>
<term>October</term>
<term>Outbreak</term>
<term>Prevaccination antibody</term>
<term>Public health laboratory</term>
<term>Recent antigenic shift</term>
<term>Significant reduction</term>
<term>Substantial protection</term>
<term>Vaccination</term>
<term>Vaccine</term>
<term>Virus strain</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.</div>
</front>
</TEI>
<istex><corpusName>elsevier</corpusName>
<keywords><teeft><json:string>vaccine</json:string>
<json:string>maize</json:string>
<json:string>influenza</json:string>
<json:string>kong strain</json:string>
<json:string>levine</json:string>
<json:string>influenza virus</json:string>
<json:string>october</json:string>
<json:string>american patients</json:string>
<json:string>influenza vaccine</json:string>
<json:string>medical officer</json:string>
<json:string>prevaccination antibody</json:string>
<json:string>substantial protection</json:string>
<json:string>vaccination</json:string>
<json:string>clinical influenza</json:string>
<json:string>normal maize</json:string>
<json:string>essential aminoacids</json:string>
<json:string>hong kong strain</json:string>
<json:string>antigenic shift</json:string>
<json:string>cancer inst</json:string>
<json:string>virus strain</json:string>
<json:string>antibody</json:string>
<json:string>antibody response</json:string>
<json:string>american controls</json:string>
<json:string>influenza outbreak</json:string>
<json:string>control group</json:string>
<json:string>significant reduction</json:string>
<json:string>influenza vaccines</json:string>
<json:string>public health laboratory</json:string>
<json:string>maize diets</json:string>
<json:string>control groups</json:string>
<json:string>maize variant</json:string>
<json:string>recent antigenic shift</json:string>
<json:string>outbreak</json:string>
</teeft>
</keywords>
<author><json:item><name>T.W. Hoskins</name>
<affiliations><json:string>Christ's Hospital, Horsham, Sussex, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>JoanR. Davies</name>
<affiliations><json:string>Public Health Laboratory, Guildford, Surrey, United Kingdom</json:string>
</affiliations>
</json:item>
<json:item><name>A. Allchin</name>
<affiliations><json:string>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</json:string>
</affiliations>
</json:item>
<json:item><name>ChristineL. Miller</name>
<affiliations><json:string>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</json:string>
</affiliations>
</json:item>
<json:item><name>T.M. Pollock</name>
<affiliations><json:string>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</json:string>
</affiliations>
</json:item>
</author>
<arkIstex>ark:/67375/6H6-KCWGV62K-F</arkIstex>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>Full-length article</json:string>
</originalGenre>
<abstract>Abstract: A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.</abstract>
<qualityIndicators><score>8.582</score>
<pdfWordCount>4038</pdfWordCount>
<pdfCharCount>24128</pdfCharCount>
<pdfVersion>1.2</pdfVersion>
<pdfPageCount>5</pdfPageCount>
<pdfPageSize>622 x 937 pts</pdfPageSize>
<refBibsNative>true</refBibsNative>
<abstractWordCount>212</abstractWordCount>
<abstractCharCount>1403</abstractCharCount>
<keywordCount>0</keywordCount>
</qualityIndicators>
<title>CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
<pmid><json:string>4124042</json:string>
</pmid>
<pii><json:string>S0140-6736(73)93062-6</json:string>
</pii>
<genre><json:string>research-article</json:string>
</genre>
<host><title>The Lancet</title>
<language><json:string>unknown</json:string>
</language>
<publicationDate>1973</publicationDate>
<issn><json:string>0140-6736</json:string>
</issn>
<pii><json:string>S0140-6736(00)X4500-X</json:string>
</pii>
<volume>302</volume>
<issue>7821</issue>
<pages><first>116</first>
<last>120</last>
</pages>
<genre><json:string>journal</json:string>
</genre>
</host>
<namedEntities><unitex><date><json:string>1970</json:string>
<json:string>1972</json:string>
<json:string>1973</json:string>
</date>
<geogName></geogName>
<orgName><json:string>National Cancer Institute grant CA 08748</json:string>
<json:string>Inc</json:string>
<json:string>New York Cancer Research Institute</json:string>
<json:string>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW</json:string>
<json:string>Health Laboratory, Guildford, Surrey CHRISTINE L</json:string>
</orgName>
<orgName_funder><json:string>National Cancer Institute grant CA 08748</json:string>
<json:string>Inc</json:string>
<json:string>New York Cancer Research Institute</json:string>
</orgName_funder>
<orgName_provider></orgName_provider>
<persName><json:string>Hong Kong</json:string>
<json:string>J. S. Nature</json:string>
<json:string>D. A. Fedn</json:string>
<json:string>E. A. Blood</json:string>
<json:string>D. E. Blood</json:string>
<json:string>J. Med</json:string>
<json:string>P. P. Cancer</json:string>
<json:string>R. A. Int</json:string>
<json:string>C. W. Cancer</json:string>
<json:string>Deward Waggoner</json:string>
<json:string>P. Ann</json:string>
<json:string>F. Kingsley</json:string>
<json:string>W.H.O. Bull</json:string>
<json:string>J. Cancer</json:string>
<json:string>N. Y. Acad</json:string>
<json:string>L. Nature</json:string>
<json:string>W. Trans</json:string>
</persName>
<placeName><json:string>United States</json:string>
<json:string>American</json:string>
<json:string>New Engl</json:string>
<json:string>N.Y.</json:string>
<json:string>New Biol</json:string>
<json:string>York</json:string>
<json:string>Postgrad</json:string>
</placeName>
<ref_url></ref_url>
<ref_bibl><json:string>Levine et al.</json:string>
</ref_bibl>
<bibl></bibl>
</unitex>
</namedEntities>
<ark><json:string>ark:/67375/6H6-KCWGV62K-F</json:string>
</ark>
<categories><wos><json:string>1 - science</json:string>
<json:string>2 - medicine, general & internal</json:string>
</wos>
<scienceMetrix><json:string>1 - health sciences</json:string>
<json:string>2 - clinical medicine</json:string>
<json:string>3 - general & internal medicine</json:string>
</scienceMetrix>
<scopus><json:string>1 - Health Sciences</json:string>
<json:string>2 - Medicine</json:string>
<json:string>3 - General Medicine</json:string>
</scopus>
<inist><json:string>1 - sciences appliquees, technologies et medecines</json:string>
<json:string>2 - sciences biologiques et medicales</json:string>
<json:string>3 - sciences medicales</json:string>
</inist>
</categories>
<publicationDate>1973</publicationDate>
<copyrightDate>1973</copyrightDate>
<doi><json:string>10.1016/S0140-6736(73)93062-6</json:string>
</doi>
<id>1E3A706172CB5F0CC5025332A21D19D172754180</id>
<score>1</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/fulltext.pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/bundle.zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher>
<availability><licence><p>elsevier</p>
</licence>
</availability>
<p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p>
<date>1973</date>
</publicationStmt>
<notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note>
<note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a">CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
<author xml:id="author-0000"><persName><forename type="first">T.W.</forename>
<surname>Hoskins</surname>
</persName>
<affiliation>Christ's Hospital, Horsham, Sussex, United Kingdom</affiliation>
</author>
<author xml:id="author-0001"><persName><forename type="first">JoanR.</forename>
<surname>Davies</surname>
</persName>
<affiliation>Public Health Laboratory, Guildford, Surrey, United Kingdom</affiliation>
</author>
<author xml:id="author-0002"><persName><forename type="first">A.</forename>
<surname>Allchin</surname>
</persName>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
</author>
<author xml:id="author-0003"><persName><forename type="first">ChristineL.</forename>
<surname>Miller</surname>
</persName>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
</author>
<author xml:id="author-0004"><persName><forename type="first">T.M.</forename>
<surname>Pollock</surname>
</persName>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
</author>
<idno type="istex">1E3A706172CB5F0CC5025332A21D19D172754180</idno>
<idno type="ark">ark:/67375/6H6-KCWGV62K-F</idno>
<idno type="DOI">10.1016/S0140-6736(73)93062-6</idno>
<idno type="PII">S0140-6736(73)93062-6</idno>
</analytic>
<monogr><title level="j">The Lancet</title>
<title level="j" type="abbrev">LANCET</title>
<idno type="pISSN">0140-6736</idno>
<idno type="PII">S0140-6736(00)X4500-X</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1973"></date>
<biblScope unit="volume">302</biblScope>
<biblScope unit="issue">7821</biblScope>
<biblScope unit="page" from="116">116</biblScope>
<biblScope unit="page" to="120">120</biblScope>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1973</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>Abstract: A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.</p>
</abstract>
</profileDesc>
<revisionDesc><change when="1973">Published</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/fulltext.txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType>
<istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>LANCET</jid>
<aid>73930626</aid>
<ce:pii>S0140-6736(73)93062-6</ce:pii>
<ce:doi>10.1016/S0140-6736(73)93062-6</ce:doi>
<ce:copyright type="unknown" year="1973"></ce:copyright>
</item-info>
<head><ce:title>CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</ce:title>
<ce:author-group><ce:author><ce:given-name>T.W.</ce:given-name>
<ce:surname>Hoskins</ce:surname>
<ce:cross-ref refid="ART3-AFF1"><ce:sup>a</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>JoanR.</ce:given-name>
<ce:surname>Davies</ce:surname>
<ce:cross-ref refid="ART3-AFF2"><ce:sup>b</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>A.</ce:given-name>
<ce:surname>Allchin</ce:surname>
<ce:cross-ref refid="ART3-AFF3"><ce:sup>c</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>ChristineL.</ce:given-name>
<ce:surname>Miller</ce:surname>
<ce:cross-ref refid="ART3-AFF3"><ce:sup>c</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:author><ce:given-name>T.M.</ce:given-name>
<ce:surname>Pollock</ce:surname>
<ce:cross-ref refid="ART3-AFF3"><ce:sup>c</ce:sup>
</ce:cross-ref>
</ce:author>
<ce:affiliation id="ART3-AFF1"><ce:label>a</ce:label>
<ce:textfn>Christ's Hospital, Horsham, Sussex, United Kingdom</ce:textfn>
</ce:affiliation>
<ce:affiliation id="ART3-AFF2"><ce:label>b</ce:label>
<ce:textfn>Public Health Laboratory, Guildford, Surrey, United Kingdom</ce:textfn>
</ce:affiliation>
<ce:affiliation id="ART3-AFF3"><ce:label>c</ce:label>
<ce:textfn>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</ce:textfn>
</ce:affiliation>
</ce:author-group>
<ce:abstract><ce:section-title>Abstract</ce:section-title>
<ce:abstract-sec><ce:simple-para>A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.</ce:simple-para>
</ce:abstract-sec>
</ce:abstract>
</head>
</converted-article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo><title>CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA"><title>CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN</title>
</titleInfo>
<name type="personal"><namePart type="given">T.W.</namePart>
<namePart type="family">Hoskins</namePart>
<affiliation>Christ's Hospital, Horsham, Sussex, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">JoanR.</namePart>
<namePart type="family">Davies</namePart>
<affiliation>Public Health Laboratory, Guildford, Surrey, United Kingdom</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">A.</namePart>
<namePart type="family">Allchin</namePart>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">ChristineL.</namePart>
<namePart type="family">Miller</namePart>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">T.M.</namePart>
<namePart type="family">Pollock</namePart>
<affiliation>Epidemiological Research Laboratory, Central Public Health Laboratory, Colindale, London NW9, United Kingdon</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre>
<originInfo><publisher>ELSEVIER</publisher>
<dateIssued encoding="w3cdtf">1973</dateIssued>
<copyrightDate encoding="w3cdtf">1973</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<abstract lang="en">Abstract: A trial of inactivated influenza vaccine containing the A/Hong Kong/68 strain was made in 800 boys in a boarding-school starting in 1970. The boys had serum samples withdrawn for antibody estimations and were allocated at random to vaccine and control groups. During an outbreak of influenza A due to the A/England/42/72 strain, all boys with clinical influenza reported to the medical officer and the diagnosis was confirmed by laboratory examination. The vaccine was shown to confer substantial protection against the new virus strain. The presence of hæmagglutinating (H.I.) antibody to either strain 6 weeks before the outbreak was associated with protection against influenza. In boys with H.I. antibody to A/Hong Kong/68 virus the attack-rate was 6%, compared with 25% in boys with no H.I. antibody to either virus strain. No influenza occurred in boys known to have H.I. antibody to the A/England/42/72 strain. Three-quarters of the boys in whom A/Hong Kong/68 H.I. antibody had been naturally acquired developed A/England/ 42/72 H.I. antibody after vaccination. In contrast, the development of A/England/42/72 H.I. antibody was less frequent after revaccination of boys in whom the A/Hong Kong/68 H.I. antibody had been induced by vaccination. A vaccine prepared from the A/Hong Kong/68 strain conferred substantial protection despite the recent antigenic shift of the influenza virus.</abstract>
<relatedItem type="host"><titleInfo><title>The Lancet</title>
</titleInfo>
<titleInfo type="abbreviated"><title>LANCET</title>
</titleInfo>
<genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre>
<originInfo><publisher>ELSEVIER</publisher>
<dateIssued encoding="w3cdtf">1973</dateIssued>
</originInfo>
<identifier type="ISSN">0140-6736</identifier>
<identifier type="PII">S0140-6736(00)X4500-X</identifier>
<part><date>1973</date>
<detail type="issue"><title>Originally published as Volume 2, Issue 7821</title>
</detail>
<detail type="volume"><number>302</number>
<caption>vol.</caption>
</detail>
<detail type="issue"><number>7821</number>
<caption>no.</caption>
</detail>
<extent unit="issue-pages"><start>111</start>
<end>166</end>
</extent>
<extent unit="pages"><start>116</start>
<end>120</end>
</extent>
</part>
</relatedItem>
<identifier type="istex">1E3A706172CB5F0CC5025332A21D19D172754180</identifier>
<identifier type="ark">ark:/67375/6H6-KCWGV62K-F</identifier>
<identifier type="DOI">10.1016/S0140-6736(73)93062-6</identifier>
<identifier type="PII">S0140-6736(73)93062-6</identifier>
<recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource>
</recordInfo>
</mods>
<json:item><extension>json</extension>
<original>false</original>
<mimetype>application/json</mimetype>
<uri>https://api.istex.fr/ark:/67375/6H6-KCWGV62K-F/record.json</uri>
</json:item>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001355 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001355 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:1E3A706172CB5F0CC5025332A21D19D172754180
   |texte=   CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN

CONTROLLED TRIAL OF INACTIVATED INFLUENZA VACCINE CONTAINING THE A/HONG KONG STRAIN DURING AN OUTBREAK OF INFLUENZA DUE TO THE A/ENGLAND/42/72 STRAIN

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri